pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 35 Non-oncology: 22
Oncology: 13
Under Consideration for Negotiation 11 Non-oncology: 6
Oncology: 5
Completed Negotiations 812 With Letter of Intent: 703
Without agreement: 109
Negotiations That Were Not Pursued 109

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Rystiggo UCB Canada Inc. Generalized myasthenia gravis (gMG)
Pemazyre Incyte Biosciences Canada Corporation For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.​
Imfinzi AstraZeneca Canada Inc. in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment
Vemlidy Gilead Sciences Canada Inc. chronic Hepatitis B virus
Spevigo Boehringer Ingelheim (Canada) Ltd. generalized pustular psoriasis (GPP)
Imdelltra Amgen Canada Inc. For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy
Fabhalta Novartis Pharmaceuticals Canada Inc. Paroxysmal nocturnal hemoglobinuria (PNH)

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
TheraSphere Y-90 Glass Micropheres Boston Scientific Corporation As selective internal radiation therapy (SIRT) for local tumor control of solitary tumors in patients with intermediate- or advanced-stage hepatocellular carcinoma (HCC), including those with recurrent or unresectable HCC. In addition to HCC
Keytruda Merck Canada Inc. For the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.
Vabysmo Hoffmann-La Roche Ltd. Retinal vein occlusion
Pexegra Jamp Pharma Corporation Febrile neutropenia in non-myeloid malignancies
Venclexta AbbVie Corporation In combination with Gazyva, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Filra Jamp Pharma Corporation Multiple Indications
Gazyva Hoffmann-La Roche Ltd. In combination with Venclexta, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Kymriah Novartis Pharmaceuticals Canada Inc. Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy
Livmarli Mirum Pharmaceuticals Inc. Alagille syndrome
Myalepta Medison Pharma Canada Inc. Leptin deficiency in lipodystrophy
Breyanzi Bristol Myers Squibb Canada Inc. Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory di
Padcev Pfizer Canada ULC In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Awiqli Novo Nordisk Canada Inc. Diabetes Mellitus, Type 2
Jardiance Boehringer Ingelheim (Canada) Ltd. Adjunct to standard of care therapy for the treatment of chronic heart failure in adults

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Ryaltris Bausch Health, Canada Inc. Seasonal allergic rhinitis